Showing 6611-6620 of 8682 results for "".
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- Survey: Mixed Sentiments for AI in Dermatologyhttps://practicaldermatology.com/news/ai-dermatology-survey-reveals-mixed-sentiments/2467817/A national survey of U.S. dermatologists reveals both enthusiasm and concern about the potential integration of artificial intelligence chatbots (AIC) into dermatological practice. The study, published in the Journal of Drugs in Dermatology, evaluated results from an online cross-sectiona
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Dietary Sodium Intake Linked to Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/dietary-sodium-intake-linked-increased-atopic-dermatitis-risk/2467760/Higher dietary sodium intake has been associated with an increased risk and severity of atopic dermatitis (AD), according to new research in JAMA Dermatology. Researchers for the cross-sectional analysis examined 215,832 participants aged 37-73 years from a UK Biobank cohort using 24-hour
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Study: Vegan Nutraceutical Improves Hair Health in Plant-Based Dietershttps://practicaldermatology.com/news/study-vegan-nutraceutical-improves-hair-health-plant-based-dieters/2467690/A recent clinical study suggested that a novel vegan nutraceutical supported hair health in women following plant-based diets. Seeking to address the nutrient deficiencies that can affect hair growth and quality in this population, researchers for the single-blind prospective study conduc
- Galderma to Pursue a Scientific Partnership with L’Oréalhttps://practicaldermatology.com/news/galderma-to-pursue-a-scientific-partnership-with-loreal/2467670/Galderma has signed a memorandum of understanding with L’Oréal to work toward a new research and development (R&D) collaboration in the form of a scientific partnership, according to a company news release. The partnership would
- Powered By MRP Gets Series A Investmenthttps://practicaldermatology.com/news/powered-mrp-gets-series-investment/2467442/“Strong tailwinds behind the aesthetics market” was part of the impetus for two prominent growth equity firms to form a strategic partnership with aesthetics device company Powered By MRP, according to a press release. The Series A investment by Aries Capital Partners and Swell Collective
- Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial of Androgenetic Alopecia Treatmenthttps://practicaldermatology.com/news/dermaliq-therapeutics-announces-positive-topline-results-phase-1b2a-trial-androgenetic-alopecia-treatment/2467422/Dermaliq Therapeutics announced statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based